November 12th 2024
A 12-week regimen showed significant reductions in wrinkle severity and pigment improvement.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
LHA serves multiple roles in acne management
September 1st 2002Paris - A new cosmetic product incorporating beta-lipohydroxyacid (LHA), a lipophilic derivative of salicylic acid, appears to be usefulwhen used alone for preventing relapses in patients who have responded toacne treatment and as an adjunct to topical tretinoin for improving thetolerability of the retinoid and shortening the onset to efficacy, accordingto results of prospective, randomized, double-blind studies presented byBrigitte Dréno, M.D., at the World Congress of Dermatology.
Combination adapalene/clindamycin hastens, improves clearing of inflammatoryacne
September 1st 2002Paris - Combination topical-antibiotic-plus-retinoid treatmentof inflammatory acne using adapalene 0.1 percent gel (Differin) with clindamycin1 percent lotion offers better efficacy and safety compared with clindamycin1 percent lotion alone, according to the results of a study presented atthe World Congress of Dermatology.
Combination clindamycin/benzoyl peroxide succeeds simply in moderate-to-severeacne
September 1st 2002New Orleans - The combination product containing clindamycin 1percent with benzoyl peroxide 5 percent in an aqueous vehicle base (BenzaClin)is a highly effective and well-tolerated treatment for patients with moderateto moderately severe acne, according to the results of two randomized, controlled,double-blind studies presented at the annual meeting of the American Academyof Dermatology.
Topical retinoids successfully stand alone
September 1st 2002Paris - Topical retinoids are highly effective as monotherapyin treating inflammatory acne and deserve a greater role in that indicationthen they often have in clinical practice, James J. Leyden, M.D., said atthe World Congress of Dermatology.
Nonablative lasers improve atrophic scars
September 1st 2002Atlanta - Nonablative treatment with a 1320nm Nd:YAG or 1450nm diode laser offers a viable option for achieving moderate improvement in the appearance of atrophic acne scars with no downtime, according to preliminary results from a randomized study conducted at the Washington Institute of Dermatologic Laser Surgery, Washington.
Amino acid accelerates wound repair
August 1st 2002Chicago - Treatment of chronic wounds, such as skin ulcers associated with aging or diabetic skin, represents an unmet medical need. Thymosin b4 (Tb4) shows promise as a therapeutic agent for wound repair in aging and diabetic patients, according to Allan L. Goldstein, Ph.D., who spoke at the annual International Symposium on Aging Skin.
Use of fillers in dark skin has nuances
August 1st 2002New York -While the use of fillers in skin of color does not differ too much from the use of fillers in people with lighter skin, there are a couple of very important points for dermatologists to consider, Derek H. Jones, M.D., said at the annual meeting of The Skin of Color Center, St. Luke's Roosevelt Hospital Center, New York.
Sunscreens evolve to broad-spectrum filtering systems
August 1st 2002New Orleans - Tremendous progress in photobiology research has led to a better understanding of skin mechanisms, permitting the development of effective sunscreens, Michele Verschoore, M.D., reported at the annual meeting of the American Academy of Dermatology.
CO2 laser accepted for blepharoplasty
July 1st 2002Orlando, Fla. Wide acceptance of blepharoplasty performedwith a carbon dioxide laser is due to the instrument's ability to allowthe surgeon to incise tissue in an almost bloodless fashion, coagulate vessels,and ablate fat without clamping, David T. Harvey, M.D., F.A.A.D., F.A.C.P.,said at the Florida Society of Dermatologic Surgeons meeting.
Excimer laser repigments facial scars
July 1st 2002Atlanta - Two recent studies suggest that the 308nm excimer laser may be the first device effective in the treatment of hypopigmented facial scars, striae, and hypopigmentation caused by resurfacing with the CO2 laser. Both studies were presented at the 22nd annual meeting of the American Society for Laser Medicine and Surgery.
Levels of sedation require derm surgeons' adherence
July 1st 2002New Orleans - Sedating patients is a serious business, and dermatologic surgeons need to be well aware of the progressive levels of sedation and ensure that patients are monitored appropriately to prevent complications, J. Lance Lichtor, M.D., said.
Buyer's remorse? Older the tattoo, the better
July 1st 2002Atlanta - Older tattoos are removed faster and more completely after laser treatment compared with newer tattoos, according to the results of a preliminary study presented by Erick A. Mafong, M.D., at the annual meeting of the American Society for Laser Medicine and Surgery.
Nd:YAG use expanded to facial telangiectasias
July 1st 2002Atlanta - Physicians may be able to expand the uses of the 1064nm Nd:YAG laser, used to treat telangiectasias and small reticular veins in the lower extremities, by also applying it to the treatment of facial telangiectasias, said David J. Goldberg, M.D., J.D., director, Skin & Laser Surgery Specialists of New York and New Jersey.
Radiofrequency device offers advantages of its own
July 1st 2002Atlanta - A new radiofrequency energy device that can nonablatively change the morphology of the dermis and allow the physician to put a high amount of energy into the skin is a huge step forward in the treatment of cosmetic conditions, said Karl Pope, director of research, Thermage, Hayward, Calif. Thermage is developing an RF device for treatment of skin in dermatology and plastic surgery applications.
Arachnophlebectomy needle proves effective for leg telangiectasias
June 1st 2002Las Vegas - Destruction of veins by a sharp-tipped needle maybe a more effective approach to leg telangiectasias than sclerotherapy,according to Linda Woodson, M.D. She views this new modality as an appropriatestrategy for sites that have been resistant to sclerotherapy, rather thanas a first-line therapy.